Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms

Maturitas

Volumn 77, Issue 1, 2014, Pages 24-31

  Mirkin, Sebastian ^a   Ryan, Kelly A ^a   Chandran, Arthi B ^a   Komm, Barry S ^a  

^a PFIZER INC   (United States)

Author keywords

Bazedoxifene; Hormone therapy; Menopause; Vasomotor symptoms

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AMENORRHEA; BREAST TENDERNESS; CLIMACTERIUM; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN DEFICIENCY; HORMONAL THERAPY; HUMAN; MASTALGIA; OSTEOLYSIS; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; SAFETY; SLEEP PARAMETERS; UTERUS BLEEDING;

BAZEDOXIFENE; HORMONE THERAPY; MENOPAUSE; VASOMOTOR SYMPTOMS;

ESTROGENS; ESTROGENS, CONJUGATED (USP); HOT FLASHES; HUMANS; INDOLES; MENOPAUSE; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84891739837     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2013.10.009     Document Type: Review

References (70)

1. H.G. Burger, E.C. Dudley, D.M. Robertson, and L. Dennerstein Hormonal changes in the menopause transition Recent Prog Horm Res 57 2002 257 275
2. E.B. Gold, A. Colvin, and N. Avis et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation Am J Public Health 96 2006 1226 1235
3. R.E. Williams, L. Kalilani, and D.B. DiBenedetti et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States Climacteric 11 2008 32 43
4. Eurostat: Population on 1 January by five years age groups and sex; 2013. Available from: http://epp.eurostat.ec.europa.eu/portal/page/portal/statistics/ search-database [cited 2013 Sep 13].
5. N.F. Col, J.R. Guthrie, M. Politi, and L. Dennerstein Duration of vasomotor symptoms in middle-aged women: a longitudinal study Menopause 16 2009 453 457
6. H.G. Burger The endocrinology of the menopause Maturitas 23 1996 129 136
7. B.L. Riggs, S. Khosla, and L.J. Melton III A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men J Bone Miner Res 13 1998 763 773
8. Fast Facts on Osteoporosis. National Osteoporosis Foundation web site; 2010. Available from: http://www.nof.org/node/40 [cited 2011 Nov 17].
9. K.B. Levine, R.E. Williams, and K.E. Hartmann Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women Menopause 15 2008 661 666
10. L.S. Cohen, C.N. Soares, A.F. Vitonis, M.W. Otto, and B.L. Harlow Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles Arch Gen Psychiatry 63 2006 385 390
11. W.H. Utian Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review Health Qual Life Outcomes 3 2005 47
12. R.E. Williams, K.B. Levine, L. Kalilani, J. Lewis, and R.V. Clark Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life Maturitas 62 2009 153 159
13. B. Ayers, and M.S. Hunter Health-related quality of life of women with menopausal hot flushes and night sweats Climacteric 16 2013 235 239
14. J.-S. Wagner, M.D. DiBonaventura, S. Shah, J. Alvir, and J. Whiteley The association of menopausal symptoms, including hot flashes, with quality of life, work productivity and resource use [abstract] Value Health 14 Suppl. 2011 A111
15. K.B. Van Dole, R.E. Williams, R.S. Brown, B. Gaynes, R. Devellis, and M.J. Funk Longitudinal association of vasomotor symptoms and psychosocial outcomes among postmenopausal women in the United States: a population-based study Menopause 17 2010 917 923
16. M. Geukes, M.P. van Aalst, M.C. Nauta, and H. Oosterhof The impact of menopausal symptoms on work ability Menopause 19 2012 278 282
17. C. Copeland Labor-force participation rates of the population age 55 and older: what did the recession do to the trends? Employee Benefit Res Inst Notes 32 2011 8 16
18. Eurostat. Employment rate of older workers; 2013. Available from: URL: http://epp.eurostat.ec.europa.eu/table.do?tab=table&int=1&plugin= 1&language=en&pcode=tsdde100 [cited 2013 Sep 13].
19. I. Lekander, F. Borgstrom, O. Strom, N. Zethraeus, and J.A. Kanis Cost-effectiveness of hormone therapy in the United States J Womens Health (Larchmt) 18 2009 1669 1677
20. M. Krychman Impact of vaginal atrophy on quality of life and sexuality OBG Manage Suppl 22 2010 S14 S19
21. N. Santoro, and J. Komi Prevalence and impact of vaginal symptoms among postmenopausal women J Sex Med 6 2009 2133 2142
22. G.P. Cumming, J. Herald, R. Moncur, H. Currie, and A.J. Lee Women's attitudes to hormone replacement therapy, alternative therapy and sexual health: a web-based survey Menopause Int 13 2007 79 83
23. S.R. Goldstein Systemic effects and endometrial safety of local estrogen therapy OBG Manage Suppl 22 2010 S20
24. J.V. Pinkerton Vaginal impact of menopause-related estrogen deficiency OBG Manage Suppl 22 2010 S2 S7
25. R. Kagan Therapeutic options for the treatment of vaginal atrophy OBG Manage Suppl 22 2010 S8 S13
26. M.B. Mac Bride, D.J. Rhodes, and L.T. Shuster Vulvovaginal atrophy Mayo Clin Proc 85 2010 87 94
27. D.W. Dempster Osteoporosis and the burden of osteoporosis-related fractures Am J Manag Care 17 Suppl. 6 2011 S164 S169
28. S.R. Salpeter, N.S. Buckley, H. Liu, and E.E. Salpeter The cost-effectiveness of hormone therapy in younger and older postmenopausal women Am J Med 122 2009 42 52
29. M.F. Botteman, N.P. Shah, J. Lian, C.L. Pashos, and J.A. Simon A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms Menopause 11 2004 343 355
30. R.L. Ohsfeldt, N.I. Gavin, and J.M. Thorp Medical care costs associated with postmenopausal estrogen plus progestogen therapy Value Health 7 2004 544 553
31. The 2012 hormone therapy position statement of: The North American Menopause Society Menopause 19 2012 257 271
32. N. Panay, H. Hamoda, R. Arya, and M. Savvas The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy Menopause Int 19 2013 59 68
33. T.J. de Villiers, M.L. Gass, and C.J. Haines et al. Global consensus statement on menopausal hormone therapy Climacteric 16 2013 203 204
34. A. Lukes Evolving issues in the clinical and managed care settings on the management of menopause following the women's health initiative J Manag Care Pharm 14 2008 7 13
35. J.E. Rossouw, G.L. Anderson, and R.L. Prentice et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
36. P.H. van de Weijer, L.A. Mattsson, and O. Ylikorkala Benefits and risks of long-term low-dose oral continuous combined hormone therapy Maturitas 56 2007 231 248
37. T.J. de Villiers, A. Pines, and N. Panay et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health Climacteric 16 2013 316 337
38. D. Grady, and G.F. Sawaya Discontinuation of postmenopausal hormone therapy Am J Med 118 Suppl. 12B 2005 163 165
39. R.J. Santen, D.C. Allred, and S.P. Ardoin et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement J Clin Endocrinol Metab 95 2010 s1 s66
40. H.S. Taylor, and J.E. Manson Update in hormone therapy use in menopause J Clin Endocrinol Metab 96 2011 255 264
41. Y. Kharode, P.V. Bodine, C.P. Miller, C.R. Lyttle, and B.S. Komm The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention Endocrinology 149 2008 6084 6091
42. D.F. Archer, V. Lewis, B.R. Carr, S. Olivier, and J.H. Pickar Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women Fertil Steril 92 2009 1039 1044
43. D.F. Archer, R.A. Lobo, K. Pan, A.A. Chines, and S. Mirkin Safety and tolerability of bazedoxifene/conjugated estrogens in postmenopausal women: findings from a 1-year, randomized, placebo- and active-controlled, phase 3 trial [abstract P-25] Menopause 18 2011 1355 1356
44. G. Bachmann, J. Bobula, and S. Mirkin Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy Climacteric 13 2010 132 140
45. R. Kagan, R.S. Williams, K. Pan, S. Mirkin, and J.H. Pickar A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women Menopause 17 2010 281 289
46. R. Lindsay, J.C. Gallagher, R. Kagan, J.H. Pickar, and G. Constantine Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women Fertil Steril 92 2009 1045 1052
47. R.A. Lobo, J.V. Pinkerton, and M.L. Gass et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile Fertil Steril 92 2009 1025 1038
48. J.V. Pinkerton, W.H. Utian, G.D. Constantine, S. Olivier, and J.H. Pickar Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial Menopause 16 2009 1116 1124
49. J.C. Gallagher, R. Lindsay, K. Pan, S. Mirkin, and A. Chines Effects of bazedoxifene/conjugated estrogens on bone mineral density and bone turnover markers in postmenopausal women: a double-blind, randomized, placebo- and active-controlled phase 3 study [abstract 1133] J Bone Miner Res 26 Suppl. 1 2011 S46
50. J.V. Pinkerton, J.A. Harvey, and K. Pan et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial Obstet Gynecol 121 2013 959 968
51. J.V. Pinkerton, K. Pan, and L. Abraham et al. Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial Menopause 2013 August 12 [Epub ahead of print]
52. S. Mirkin, B.S. Komm, K. Pan, and A.A. Chines Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women Climacteric 16 2013 338 346
53. H. Yu, J. Racketa, S. Mirkin, and A. Chines Hot flush symptom-free days with bazedoxifene/conjugated estrogens in a randomized, controlled trial of postmenopausal women [abstract P-56] Menopause 17 2010 1238
54. W. Utian, H. Yu, J. Bobula, S. Mirkin, S. Olivier, and J.H. Pickar Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women Maturitas 63 2009 329 335
55. A.H. MacLennan, J.L. Broadbent, S. Lester, and V. Moore Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes Cochrane Database Syst Rev 2004 CD002978
56. J.V. Pinkerton, A.A. Chines, J. Racketa, and S. Mirkin Menopause-related quality of life and satisfaction in postmenopausal women treated with bazedoxifene/conjugated estrogens (BZA/CE) [abstract S-12] Menopause 17 2010 1219
57. J.V. Pinkerton, A.A. Chines, J. Racketa, and S. Mirkin Bazedoxifene/conjugated estrogens (BZA/CE): effect on sleep parameters in postmenopausal women [abstract P-53] Menopause 17 2010 1237 1238
58. J.V. Pinkerton, A.G. Bushmakin, J. Racketa, J.C. Cappelleri, A.A. Chines, and S. Mirkin Direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance [abstract] Presented at the World Congress on Menopause June 8-11, Rome, Italy 2011
59. J.A. Harvey, J.V. Pinkerton, K. Pan, J.R. Thompson, S. Mirkin, and A.A. Chines The effects of bazedoxifene/conjugated estrogens on breast density in postmenopausal women [abstract S-1] Menopause 18 2011 1342
60. M. Hickey, and I.S. Fraser Surface vascularization and endometrial appearance in women with menorrhagia or using levonorgestrel contraceptive implants, Implications for the mechanisms of breakthrough bleeding Hum Reprod 17 2002 2428 2434
61. S. Palacios, T.J. de Villiers, and F.C. Nardone et al. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study Maturitas 76 2013 81 87
62. V.M. Barnabei, B.B. Cochrane, and A.K. Aragaki et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative Obstet Gynecol 105 2005 1063 1073
63. C.J. Crandall, A. Karlamangla, M.H. Huang, G. Ursin, M. Guan, and G.A. Greendale Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy Arch Intern Med 166 2006 1578 1584
64. J.A. Harvey, J.V. Pinkerton, E.C. Baracat, H. Shi, A.A. Chines, and S. Mirkin Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens Menopause 20 2013 138 145
65. J.H. Pickar, I.T. Yeh, G. Bachmann, and L. Speroff Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy Fertil Steril 92 2009 1018 1024
66. J.V. Pinkerton, H. Taylor, K. Pan, and A. Chines Breast parameters with bazedoxifene/conjugated estrogens in randomized, controlled trials of postmenopausal women [abstract] Menopause 17 2010 1221 1222
67. S. Mirkin, D.F. Archer, R.A. Lobo, K. Pan, and A.A. Chines Safety and tolerability of bazedoxifene/conjugated estrogens in postmenopausal women: findings from a 1-year, randomized, placebo- and active-controlled, phase 3 trial [abstract] Presented at the European Congress on Menopause and Andropause March 28-31, Athens, Greece 2012
68. V. Lewis Undertreatment of menopausal symptoms and novel options for comprehensive management Curr Med Res Opin 25 2009 2689 2698
69. J.E. Manson 4th ed. Overview of menopause. Menopause practice: a clinician's guide 2010 The North American Menopause Society Mayfield Heights, OH 1.1 1.5
70. S. Mirkin, H.S. Taylor, D.F. Archer, J.H. Pickar, J. Thompson, and B.S. Komm Differential effects of bazedoxifene/conjugated estrogens and hormone therapy on the endometrium [abstract] Presented at the: annual meeting of the North American Menopause Society October 3-6, Orlando, FL 2012